68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Sep 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to guide radiation therapy for patients with advanced clear cell renal cell carcinoma (ccRCC), which is a type of kidney cancer. Researchers are looking at a special imaging technique using a tracer called 68Ga-NY104. This tracer helps identify cancer cells more effectively, which could lead to better-targeted treatment when combined with standard therapy. The goal is to see if this approach improves outcomes for patients whose cancer has spread or come back after treatment.

To be eligible for this trial, participants need to be at least 18 years old and have a confirmed diagnosis of clear cell renal cell carcinoma. They should have no more than 10 cancer spots and be expected to live for at least three months. Participants will undergo imaging tests and receive radiation therapy along with standard cancer treatments. It's important to note that individuals with certain conditions, such as brain metastasis or active infections, cannot participate. This study is currently recruiting, and all participants will need to provide written consent.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old
• • Histologically or cytologically confirmed clear cell renal cell carcinoma
• • Eligible for radiation therapy: no more than 10 lesions in total
• • Expected survival: over 3 months
• • ECOG: 0 or 1
• • Sufficient organ function
• • Written informed consent
• Exclusion Criteria:
• • Brain metastasis/carcinomatous meningitis
• • Other malignant tumors that are not controlled within 5 years, except for non-metastatic low-risk prostate cancer.
• • Pregnant or breastfeeding.
• • Active infection.